Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0CDYJL)

ADC Name	MYTX-011
Synonyms	MYTX-011 Click to Show/Hide
Organization	Mythic Therapeutics (Originator)
Drug Status	Phase 1 (discontinued)
Drug-to-Antibody Ratio	2
Structure
		2D MOL
Antibody Name	Anti-c-MET pH-dependent mAb		Antibody Info
Antigen Name	Hepatocyte growth factor receptor (MET)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Payload Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random Cysteines
Combination Type	vedotin

2027 Update

The disease landscape of This ADC

2027 Update

The clinical trial pipelines of This ADC

Indication

Phase 1

Phase 2

Phase 3

Approved

Lung cancer

1 Trials

Trial ID
TWCT00002441; NCT05652868; ISRCTN57038506; EUCT2023-504630-22-00

2027 Update

ADC-specific functional property

Binding Affinity

Click To Hide/Show 2 ADC-specific functional property Data

Dissocation Constant (Kd)	Binding Target	Description	Reference
4 nM	cMET	Binding affinity of MYTX-011 to recombinant human cMET (pH 7.4).	[1]
9.44 nM	cMET	Binding affinity of MYTX-011 to recombinant cymomolgus monkey cMET (pH 7.4).	[1]

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT05652868	PHASE1	A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01
Undisclosed	NCT05652868	Phase 1	A phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate MYTX-011 in subjects with non-small cell lung cancer - kismet-01.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[2]
Patients Enrolled	Inclusion: NSCLC patients (Part 1: advanced/metastatic; Part 2: stratified by cMET expression/EGFR status) with ≥1 measurable lesion, ECOG 0-1, prior SOC therapy. Exclusion: Recent radiation/surgery (6w/28d), active CNS metastases, interstitial lung disease, Grade>1 neuropathy, hepatic/corneal disorders, or uncontrolled infections. Contraception required for 6 months post-treatment. Click to Show/Hide
Administration Dosage	MYTX-011 will be administered as an intravenous infusion every 21 days.
*Related Clinical Trial*
NCT Number	NCT05652868	Clinical Status	PHASE1
Clinical Description	A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01
Primary Endpoint	Primary endpoints include DLT assessment (treatment-related AEs) in Part 1 (21-day evaluation) and tumor response rate (CR+PR) in Part 2 (2-year follow-up).
Other Endpoint	Secondary objectives comprise PK analysis (total ADC/antibody/free MMAE), ADA detection, ORR/DOR/TTR/DCR assessment, and survival outcomes (PFS/OS) with 24-month monitoring in Part 1.
Experiment 2 Reporting the Activity Date of This ADC				[3]
*Related Clinical Trial*
NCT Number	NCT05652868	Clinical Status	Phase 1
Clinical Description	A phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate MYTX-011 in subjects with non-small cell lung cancer - kismet-01.

References

Ref 1	MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells
Ref 2	Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Ref 3	A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01, NCT05652868